RETAPAMULIN: 19 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
19
Total FAERS Reports
0
Deaths Reported
9
Hospitalizations
19
As Primary/Secondary Suspect
Apr 12, 2007
FDA Approved
Discontinued
Status
FDA Application: 022055 ·
Patent Expires: Feb 14, 2027 · First Report: 2014 · Latest Report: 20180314
What Are the Most Common RETAPAMULIN Side Effects?
#1 Most Reported
Linear iga disease
7 reports (36.8%)
#2 Most Reported
Erythema multiforme
6 reports (31.6%)
#3 Most Reported
Application site pain
3 reports (15.8%)
All RETAPAMULIN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Linear iga disease | 7 | 36.8% | 0 | 7 |
| Erythema multiforme | 6 | 31.6% | 0 | 6 |
Who Reports RETAPAMULIN Side Effects? Age & Gender Data
Gender: 27.3% female, 72.7% male. Average age: 20.3 years. Most reports from: US. View detailed demographics →
Is RETAPAMULIN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2014 | 2 | 0 | 1 |
| 2016 | 1 | 0 | 0 |
| 2017 | 3 | 0 | 0 |
| 2018 | 1 | 0 | 0 |
What Is RETAPAMULIN Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 11 |
Official FDA Label for RETAPAMULIN
Official prescribing information from the FDA-approved drug label.